A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma

We present results of a prospective, multicenter, phase II study evaluating rituximab, bendamustine, bortezomib and dexamethasone as first-line treatment for patients with mantle cell lymphoma aged 65 years or older. A total of 74 patients were enrolled (median age, 73 years). Patients received a ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Gressin, Rémy, Daguindau, Nicolas, Tempescul, Adrian, Moreau, Anne, Carras, Sylvain, Tchernonog, Emmanuelle, Schmitt, Anna, Houot, Roch, Dartigeas, Caroline, Pignon, Jean Michel, Corm, Selim, Banos, Anne, Mounier, Christiane, Dupuis, Jehan, Macro, Margaret, Fleury, Joel, Jardin, Fabrice, Sarkozy, Clementine, Damaj, Ghandi, Feugier, Pierre, Fornecker, Luc Matthieu, Chabrot, Cecile, Dorvaux, Veronique, Bouadallah, Krimo, Amorin, Sandy, Garidi, Reda, Voillat, Laurent, Joly, Bertrand, Celigny, Philippe Solal, Morineau, Nadine, Moles, Marie Pierre, Zerazhi, Hacene, Fontan, Jean, Arkam, Yazid, Alexis, Magda, Delwail, Vincent, Vilque, Jean Pierre, Ysebaert, Loic, Le Gouill, Steven, Callanan, Mary B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312036/
https://www.ncbi.nlm.nih.gov/pubmed/30171024
http://dx.doi.org/10.3324/haematol.2018.191429

Ejemplares similares

Ejemplares similares